Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 856273 | ISIN: JP3942400007 | Ticker-Symbol: YPH
Tradegate
28.03.24
17:27 Uhr
9,882 Euro
-0,116
-1,16 %
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
ASTELLAS PHARMA INC Chart 1 Jahr
5-Tage-Chart
ASTELLAS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,91810,07528.03.
9,89810,10528.03.

Aktuelle News zur ASTELLAS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:46China NMPA accepts Astellas' sBLA for urothelial cancer treatment2
DoDividendenbekanntmachungen (28.03.2024)4.053 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ACOM CO LTD  JP3108600002  6 JPY  0,0366 EUR  ADVANEX INC  JP3213400009  20 JPY  0,1222 EUR  AICA KOGYO CO LTD  JP3100800006  59 JPY  0...
► Artikel lesen
DoAstellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China311BEIJING (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced that China's National Medical Products Administration or NMPA has accepted the supplemental Biologics License Application or sBLA for...
► Artikel lesen
DoPfizer, Astellas first-line bladder cancer therapy accepted for review in China11
MiJapan clears first CLDN18.2 drug, Astellas' Vyloy5
DiAstellas secures approval for gastric cancer antibody in Japan4
DiAstellas' Vyloy Approved In Japan For Gastric Cancer220TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) announced on Tuesday that Japan's Ministry of Health, Labour and Welfare has approved Vyloy or zolbetuximab, an anti-claudin 18.2 also known as...
► Artikel lesen
DiAstellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy612Permanent J-code J2782 effective April 1, 2024 NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today...
► Artikel lesen
DiPfizer/Astellas' Xtandi receives CHMP recommendation to treat recurrent prostate cancer25
DiAstellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer155VYLOY approved in combination with chemotherapy for patients with human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer MHLW...
► Artikel lesen
22.03.Astellas Pharma Gets Positive CHMP Opinion For XTANDI In Early Prostate Cancer Treatment Setting223TOKYO (dpa-AFX) - Astellas Pharma Inc. announced Friday the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending...
► Artikel lesen
22.03.Astellas Pharma Inc.: Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting122- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations...
► Artikel lesen
19.03.With new data, Bayer readies rival to Astellas menopause drug50
19.03.Bayer ready to take rival to Astellas' Veozah to regulators after phase 3 hat trick42
19.03.Bayer cues up filings for rival to Astellas' menopause drug22
14.03.Astellas puts the cork back in $350M Xork deal after Cartesian-Selecta merger11
11.03.Astellas wins FDA orphan drug status for approved antifungal Cresemba8
11.03.Astellas Receives FDA Orphan Drug, Pediatric Exclusivities For Cresemba438TOKYO (dpa-AFX) - Monday, Astellas Pharma Inc. (ALPMY) announced that Cresemba, also known as isavuconazonium sulfate, has been granted orphan drug and pediatric exclusivity by the FDA. This...
► Artikel lesen
11.03.Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics198Agreement leverages Ubiquigent's DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics Ubiquigent...
► Artikel lesen
04.03.Astellas Pharma Inc.: Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan110TOKYO, March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT 2 Phase 3 pivotal...
► Artikel lesen
Seite:  Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4